Credit Suisse initiated coverage on VectivBio with a new price target
$VECT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Credit Suisse initiated coverage of VectivBio with a rating of Outperform and set a new price target of $24.00